The collaboration will integrate both companies expertise in antibody discovery and manufacturing services
Abzena, a specialist in end-to-end integrated CDMO of complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, have formed a strategic partnership.
The collaboration will see the integration of Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services to provide biopharma customers with a streamlined, end-to-end drug development solution.
Mabqi and Abzena have formed their partnership to create a solution capable of enabling drug developers to bridge from discovery through lead candidate selection into pre-clinical development and beyond. Through this collaboration, customers will be able to benefit from the combined scientific and technical support, simplified workflows, and shortened development timelines.
The partnership’s combined offerings will utilise Mabqi’s LiteMab Antibody Discovery Studio for hit screening, characterisation, and hit selection using universal and pH-sensitive libraries to identify top lead candidates, and use Abzena’s capabilities for developability, cell line development, process development, and GMP manufacturing. The organisations have expertise in supporting a range of modalities, including monoclonal antibodies (mAbs), mAb fragments, bi- and multi-specifics, and bioconjugates.
Campbell Bunce, CSO at Abzena, said, “Our partnership with Mabqi brings together two science-rich organisations that are focused on advancing antibody innovation through integration. The combination of our capabilities enables us to significantly accelerate our customers’ discovery programs from end-to-end by leveraging data to streamline and de-risk earlier on in development, enabling a faster and more successful path to the clinic.”
Sylvain Yon, CEO of Mabqi, said, “Our strategic partnership with Abzena marks a significant milestone in offering an integrated antibody discovery-through-development solution by combining our complementary scientific expertise and advanced capabilities. Beyond scientific excellence and innovation, what truly sets this collaboration apart is the exceptional human fit between our teams, ensuring smooth cooperation, shared dedication to innovation and a customer-focused relationship. Together, we are poised to accelerate the development of differentiated therapeutic antibodies that can make a meaningful impact for patients worldwide.”
